In patients with HIV infection, a switch to long acting cabotegravir plus rilpivirine shows no clinically meaningful changes in body composition or adverse metabolic effects over 48 weeks.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/long-acting-hiv-drug-switch-shows-no-major-metabolic-impact-2026a10005vf?src=rss
Author :
Publish date : 2026-02-25 04:53:00
Copyright for syndicated content belongs to the linked Source.
